
Arthur L. Corbin
Examiner (ID: 24)
| Most Active Art Unit | 1302 |
| Art Unit(s) | 1794, 1302, 1761 |
| Total Applications | 1985 |
| Issued Applications | 1221 |
| Pending Applications | 190 |
| Abandoned Applications | 573 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17748052
[patent_doc_number] => 20220226255
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-21
[patent_title] => ENCAPSULATION OF MESSENGER RNA
[patent_app_type] => utility
[patent_app_number] => 17/539659
[patent_app_country] => US
[patent_app_date] => 2021-12-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11148
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 1
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17539659
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/539659 | ENCAPSULATION OF MESSENGER RNA | Nov 30, 2021 | Pending |
Array
(
[id] => 17370283
[patent_doc_number] => 20220025335
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-27
[patent_title] => MUSCULAR DYSTROPHY CHIMERIC CELLS AND METHOD FOR TREATING MUSCULAR DYSTROPHIES
[patent_app_type] => utility
[patent_app_number] => 17/498901
[patent_app_country] => US
[patent_app_date] => 2021-10-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6395
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 70
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17498901
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/498901 | MUSCULAR DYSTROPHY CHIMERIC CELLS AND METHOD FOR TREATING MUSCULAR DYSTROPHIES | Oct 11, 2021 | Pending |
Array
(
[id] => 17685978
[patent_doc_number] => 20220193270
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-23
[patent_title] => METHOD FOR ENHANCING TUMOR GROWTH
[patent_app_type] => utility
[patent_app_number] => 17/449932
[patent_app_country] => US
[patent_app_date] => 2021-10-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25344
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 68
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17449932
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/449932 | METHOD FOR ENHANCING TUMOR GROWTH | Oct 3, 2021 | Abandoned |
Array
(
[id] => 17760058
[patent_doc_number] => 20220233670
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-28
[patent_title] => INDUCED ACTIVATION IN DENDRITIC CELLS
[patent_app_type] => utility
[patent_app_number] => 17/478488
[patent_app_country] => US
[patent_app_date] => 2021-09-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27041
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17478488
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/478488 | INDUCED ACTIVATION IN DENDRITIC CELLS | Sep 16, 2021 | Abandoned |
Array
(
[id] => 20193538
[patent_doc_number] => 20250270248
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-08-28
[patent_title] => OLIGONUCLEOTIDES CONJUGATED TO FATTY ACIDS
[patent_app_type] => utility
[patent_app_number] => 18/245422
[patent_app_country] => US
[patent_app_date] => 2021-09-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12300
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18245422
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/245422 | OLIGONUCLEOTIDES CONJUGATED TO FATTY ACIDS | Sep 14, 2021 | Abandoned |
Array
(
[id] => 19717374
[patent_doc_number] => 12202897
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-01-21
[patent_title] => Drug regulated transgene expression
[patent_app_type] => utility
[patent_app_number] => 17/472284
[patent_app_country] => US
[patent_app_date] => 2021-09-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 27
[patent_no_of_words] => 55751
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 96
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17472284
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/472284 | Drug regulated transgene expression | Sep 9, 2021 | Issued |
Array
(
[id] => 17297897
[patent_doc_number] => 20210393736
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-23
[patent_title] => NOVEL RECOMBINANT EXOSOME AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/467050
[patent_app_country] => US
[patent_app_date] => 2021-09-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7934
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17467050
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/467050 | NOVEL RECOMBINANT EXOSOME AND USE THEREOF | Sep 2, 2021 | Abandoned |
Array
(
[id] => 18692943
[patent_doc_number] => 20230323302
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-12
[patent_title] => COMBATING COVID-19 USING ENGINEERED INKT CELLS
[patent_app_type] => utility
[patent_app_number] => 18/044000
[patent_app_country] => US
[patent_app_date] => 2021-09-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10923
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18044000
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/044000 | COMBATING COVID-19 USING ENGINEERED INKT CELLS | Sep 2, 2021 | Abandoned |
Array
(
[id] => 18581575
[patent_doc_number] => 20230263827
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-24
[patent_title] => EXPANDED MEMORY SUBSETS OF GAMMA DELTA T CELLS FOR IMMUNOTHERAPY
[patent_app_type] => utility
[patent_app_number] => 18/043660
[patent_app_country] => US
[patent_app_date] => 2021-09-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16342
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -50
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18043660
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/043660 | EXPANDED MEMORY SUBSETS OF GAMMA DELTA T CELLS FOR IMMUNOTHERAPY | Sep 1, 2021 | Pending |
Array
(
[id] => 18595992
[patent_doc_number] => 20230270783
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => IMMUNE SYSTEM RESTORATION BY CELL THERAPY
[patent_app_type] => utility
[patent_app_number] => 18/043576
[patent_app_country] => US
[patent_app_date] => 2021-08-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10892
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18043576
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/043576 | IMMUNE SYSTEM RESTORATION BY CELL THERAPY | Aug 24, 2021 | Pending |
Array
(
[id] => 17273004
[patent_doc_number] => 20210379202
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-09
[patent_title] => INTRATHECAL ADMINISTRATION OF ADENO-ASSOCIATED-VIRAL VECTORS FOR GENE THERAPY
[patent_app_type] => utility
[patent_app_number] => 17/407782
[patent_app_country] => US
[patent_app_date] => 2021-08-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12225
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 86
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17407782
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/407782 | INTRATHECAL ADMINISTRATION OF ADENO-ASSOCIATED-VIRAL VECTORS FOR GENE THERAPY | Aug 19, 2021 | Abandoned |
Array
(
[id] => 17292542
[patent_doc_number] => 20210388381
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-16
[patent_title] => Hepatocyte Based Insulin Gene Therapy for Diabetes
[patent_app_type] => utility
[patent_app_number] => 17/403138
[patent_app_country] => US
[patent_app_date] => 2021-08-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8142
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 106
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17403138
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/403138 | Hepatocyte based insulin gene therapy for diabetes | Aug 15, 2021 | Issued |
Array
(
[id] => 17255797
[patent_doc_number] => 20210368782
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-02
[patent_title] => NUCLEATED CELL PRESERVATION BY LYOPHILIZATION
[patent_app_type] => utility
[patent_app_number] => 17/401474
[patent_app_country] => US
[patent_app_date] => 2021-08-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7109
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 136
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17401474
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/401474 | NUCLEATED CELL PRESERVATION BY LYOPHILIZATION | Aug 12, 2021 | Abandoned |
Array
(
[id] => 18658010
[patent_doc_number] => 20230303974
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-28
[patent_title] => Immune Cells Defective for SOCS1
[patent_app_type] => utility
[patent_app_number] => 18/018635
[patent_app_country] => US
[patent_app_date] => 2021-07-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39689
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18018635
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/018635 | Immune Cells Defective for SOCS1 | Jul 29, 2021 | Pending |
Array
(
[id] => 17297964
[patent_doc_number] => 20210393803
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-23
[patent_title] => IMMUNOMODULATORY ONCOLYTIC ADENOVIRAL VECTORS, AND METHODS OF PRODUCTION AND USE THEREOF FOR TREATMENT OF CANCER
[patent_app_type] => utility
[patent_app_number] => 17/385265
[patent_app_country] => US
[patent_app_date] => 2021-07-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32867
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 164
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17385265
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/385265 | IMMUNOMODULATORY ONCOLYTIC ADENOVIRAL VECTORS, AND METHODS OF PRODUCTION AND USE THEREOF FOR TREATMENT OF CANCER | Jul 25, 2021 | Abandoned |
Array
(
[id] => 17673084
[patent_doc_number] => 20220186251
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-16
[patent_title] => VIRAL VECTORS FOR THE TREATMENT OF DIABETES
[patent_app_type] => utility
[patent_app_number] => 17/384533
[patent_app_country] => US
[patent_app_date] => 2021-07-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27720
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17384533
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/384533 | VIRAL VECTORS FOR THE TREATMENT OF DIABETES | Jul 22, 2021 | Pending |
Array
(
[id] => 17874402
[patent_doc_number] => 11446395
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-09-20
[patent_title] => AAV vector for treatment of Friedreich's ataxia
[patent_app_type] => utility
[patent_app_number] => 17/365614
[patent_app_country] => US
[patent_app_date] => 2021-07-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 10
[patent_no_of_words] => 12402
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17365614
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/365614 | AAV vector for treatment of Friedreich's ataxia | Jun 30, 2021 | Issued |
Array
(
[id] => 17168901
[patent_doc_number] => 20210322571
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-21
[patent_title] => AAV VECTOR FOR TREATMENT OF FRIEDREICH'S ATAXIA
[patent_app_type] => utility
[patent_app_number] => 17/365845
[patent_app_country] => US
[patent_app_date] => 2021-07-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12354
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17365845
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/365845 | AAV VECTOR FOR TREATMENT OF FRIEDREICH'S ATAXIA | Jun 30, 2021 | Pending |
Array
(
[id] => 18510120
[patent_doc_number] => 20230226221
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-20
[patent_title] => USE OF RECOMBINANT HUMAN ACID SPHINGOMYELINASE TO IMPROVE SKELETAL MYOFIBER REPAIR
[patent_app_type] => utility
[patent_app_number] => 18/008422
[patent_app_country] => US
[patent_app_date] => 2021-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12803
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18008422
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/008422 | USE OF RECOMBINANT HUMAN ACID SPHINGOMYELINASE TO IMPROVE SKELETAL MYOFIBER REPAIR | Jun 28, 2021 | Pending |
Array
(
[id] => 17156123
[patent_doc_number] => 20210317174
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-14
[patent_title] => COMPOSITIONS AND METHODS FOR DELIVERING CFTR POLYPEPTIDES
[patent_app_type] => utility
[patent_app_number] => 17/356214
[patent_app_country] => US
[patent_app_date] => 2021-06-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29995
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17356214
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/356214 | COMPOSITIONS AND METHODS FOR DELIVERING CFTR POLYPEPTIDES | Jun 22, 2021 | Abandoned |